

Please type a plus sign (+) inside this box → ☒

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number


UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No.	16842-760	Total Pages	81
	First Named Inventor or Application Identifier			
	Kenneth J. LIVAK et al., "Hybridization Assay Using Self-Quenching Fluorescence Probe"			
	Express Mail Label No.	EL324593567 US		

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	6. <input type="checkbox"/> Microfiche Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Specification [Total Pages <u>54</u>] (preferred arrangement set forth below) <ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R&D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings- Detailed Description- Claim(s)- Abstract of the Disclosure	7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ul style="list-style-type: none">a. <input checked="" type="checkbox"/> Computer Readable Copyb. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)c. <input checked="" type="checkbox"/> Statement verifying identity of above copies
3. <input checked="" type="checkbox"/> Drawing(s) (37 CFR 1.152) [Total Sheets <u>2</u>]	8. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & documents(s))
4. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages <u>4</u>] <ul style="list-style-type: none">a. <input type="checkbox"/> Newly executed (original or copy)b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below]<ul style="list-style-type: none">i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	9. <input checked="" type="checkbox"/> 37 CFR 3.73(b) Statement [X] Power of Attorney by Assignee (when there is an assignee)
5. <input checked="" type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	10. <input type="checkbox"/> English Translation Document (if applicable)
	11. <input type="checkbox"/> Information Disclosure Statement (IDS) PTO-1449 [] Copies of IDS Citations
	12. <input checked="" type="checkbox"/> Preliminary Amendment (2 pages)
	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
	14. <input type="checkbox"/> Small Entity Statement(s) [] Statement filed in prior application, Status still proper and desired
	15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)
	16. <input checked="" type="checkbox"/> Other: Express Mail Statement (37 CFR 1.10)

16. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

☒ Continuation [] Divisional [] Continuation-in-part (CIP) of prior application No. 09/ 207,170

17. CORRESPONDING ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label		 21971 Insert Customer No. or Attach bar code label here)		or <input type="checkbox"/> Correspondence address below	
NAME		PATENT TRADEMARK OFFICE			
ADDRESS					
CITY	STATE	ZIP CODE			
COUNTRY	TELEPHONE	FAX			

SUBMITTED BY

Typed or

Printed Name

David J. Weitz

Signature

David J. Weitz

Reg. Number 38,362

Date November 8, 1999

EXPRESS MAIL LABEL NO.: EL324593567US

PATENT
Attorney Docket No. 16842-760

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Kenneth J. Livak et al.) Group Art Unit: Unknown
)
Application No. Unassigned) Examiner: Unknown
(Continuation of USSN: 09/207,170))
)
Filed: Herewith)
)
For: HYBRIDIZATION ASSAY USING SELF-)
QUENCHING FLUORESCENCE PROBE)
)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified patent application on the merits, please amend the application as follows:

IN THE SPECIFICATION:

In the specification, page 1, under the heading "Relationship to Copending Applications", please delete the entire paragraph beginning at line 17 and replace it with the following:

--This application is a continuation of Application Serial No. 09/207,170, filed December 7, 1998, which is a continuation of Application Serial No. 08/558,303, filed November 15, 1995, now U.S. Patent No. 5,876,930, which is a continuation of Application Serial No. 08/340,558, filed November 16, 1994, now U.S. Patent No. 5,538,848, each of which is incorporated herein by reference in its entirety.--

IN THE CLAIMS:

Please cancel claims 2-40 without prejudice or disclaimer.

REMARKS


Entry of the above-identified Preliminary Amendment prior to examination on the merits is respectfully requested.

The Commissioner is authorized to charge any additional fees which may be required, including petition fees and extension of time fees, or credit any overpayment to Deposit Account No. 23-2415 (Docket No. 16842-760).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

By:


David J. Weitz
Registration No. 38,362

650 Page Mill Road
Palo Alto, California 94304
(650) 493-9300

Date: Nov. 8, 1999

HYBRIDIZATION ASSAY USING SELF-QUENCHING FLUORESCENCE PROBE

Inventors: Kenneth J. Livak, Susan J. A. Flood,
Jeffrey Maramaro and Khairuzzaman Bashar Mullah

BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates generally to fluorescent probes which include a fluorescent reporter molecule and a fluorescent quencher molecule. More specifically, the invention relates to fluorescent probes which include a fluorescent reporter molecule and a fluorescent quencher molecule which may be used in hybridization assays and in nucleic acid amplification reactions, especially polymerase chain reactions (PCR).

Relationship to Copending Application

This application is a continuation of Application Ser. No. 08/340,558, filed November 16, 1994, which is incorporated herein by reference.

Description of Related Art

Fluorescent reporter molecule - quencher molecule pairs have been incorporated onto oligonucleotide probes in order to monitor biological events based on the fluorescent reporter molecule and quencher molecule being separated or brought within a minimum quenching distance of each other. For example, probes have been developed where the intensity of the reporter molecule fluorescence increases due to the separation of the reporter molecule from the quencher molecule. Probes have also been developed which lose their fluorescence because the quencher molecule is brought into proximity with the reporter molecule. These reporter - quencher molecule pair

probes have been used to monitor hybridization assays and nucleic acid amplification reactions, especially polymerase chain reactions (PCR), by monitoring either the appearance or disappearance of the fluorescence signal generated by the reporter molecule.

5 As used herein, a reporter molecule is a molecule capable of generating a fluorescence signal. A quencher molecule is a molecule capable of absorbing the fluorescence energy of an excited reporter molecule, thereby quenching the fluorescence signal that would otherwise be released from the excited reporter molecule. In order for a
10 quencher molecule to quench an excited fluorophore, the quencher molecule must be within a minimum quenching distance of the excited reporter molecule at some time prior to the reporter molecule releasing the stored fluorescence energy.

15 Probes containing a reporter molecule - quencher molecule pair have been developed for hybridization assays where the probe forms a hairpin structure, i.e., where the probe hybridizes to itself to form a loop such that the quencher molecule is brought into proximity with the reporter molecule in the absence of a complementary nucleic acid sequence to prevent the formation of the hairpin structure. WO
20 90/03446; European Patent Application No. 0 601 889 A2. When a complementary target sequence is present, hybridization of the probe to the complementary target sequence disrupts the hairpin structure and causes the probe to adopt a conformation where the quencher molecule is no longer close enough to the reporter molecule to quench the
25 reporter molecule. As a result, the probes provide an increased fluorescent signal when hybridized to a target sequence than when unhybridized. Probes including a hairpin structure have the disadvantage that they can be difficult to design and may interfere with the hybridization of the probe to the target sequence.

Assays have also been developed for identifying the presence of a hairpin structure using two separate probes, one containing a reporter molecule and the other a quencher molecule. Mergney, *et al.*, Nucleic Acids Research, 22:6 920-928 (1994). In these assays, the
5 fluorescence signal of the reporter molecule decreases when hybridized to the target sequence due to the quencher molecule being brought into proximity with the reporter molecule.

One particularly important application for probes including a reporter - quencher molecule pair is their use in nucleic acid
10 amplification reactions, such as polymerase chain reactions (PCR), to detect the presence and amplification of a target nucleic acid sequence. In general, nucleic acid amplification techniques have opened broad new approaches to genetic testing and DNA analysis. Arnheim and Erlich, Ann. Rev. Biochem., 61: 131-156 (1992). PCR, in particular, has
15 become a research tool of major importance with applications in, for example, cloning, analysis of genetic expression, DNA sequencing, genetic mapping and drug discovery. Arnheim and Erlich, Ann. Rev. Biochem., 61: 131-156 (1992); Gilliland *et al.*, Proc. Natl. Acad. Sci., 87: 2725-2729 (1990); Bevan *et al.*, PCR Methods and Applications, 1: 222-
20 228 (1992); Green *et al.*, PCR Methods and Applications, 1: 77-90 (1991); Blackwell *et al.*, Science, 250: 1104-1110 (1990).

The widespread applications of nucleic acid amplification techniques has driven the development of instrumentation for carrying out the amplification reactions under a variety of circumstances.
25 Important design goals for such instrument development have included fine temperature control, minimization of sample-to-sample variability in multi-sample thermal cycling, automation of pre- and post-reaction processing steps, high speed temperature cycling, minimization of sample volumes, real time measurement of amplification products and

minimization of cross contamination. for example, due to "sample
carryover". In particular, the design of instruments permitting
amplification to be carried out in closed reaction chambers and
monitored in real time would be highly desirable for preventing cross-
contamination. Higuchi *et al.*, *Biotechnology*, 10: 413-417 (1992) and
11: 1026-1030 (1993); and Holland *et al.*, *Proc. Natl. Acad. Sci.*, 88:
7276-7280 (1991). Clearly, the successful realization of such a design
goal would be especially desirable in the analysis of diagnostic samples,
where a high frequency of false positives and false negatives, for
example caused by "sample carryover", would severely reduce the
value of an amplification procedure. Moreover, real time monitoring of
an amplification reaction permits far more accurate quantification of
starting target DNA concentrations in multiple-target amplifications, as
the relative values of close concentrations can be resolved by taking into
account the history of the relative concentration values during the
reaction. Real time monitoring also permits the efficiency of the
amplification reaction to be evaluated, which can indicate whether
reaction inhibitors are present in a sample.

Holland *et al.* (cited above), U.S. Patent No. 5,210,015 to
Gelfand, *et al.* and others have proposed fluorescence-based
approaches to provide real time measurements of amplification products
during PCR. Such approaches have either employed intercalating dyes
(such as ethidium bromide) to indicate the amount of double-stranded
DNA present, or they have employed probes containing fluorescence-
quencher pairs (also referred to as the "Taq-Man" approach) where the
probe is cleaved during amplification to release a fluorescent molecule
whose concentration is proportional to the amount of double-stranded
DNA present. During amplification, the probe is digested by the
nuclease activity of a polymerase when hybridized to the target

sequence to cause the fluorescent molecule to be separated from the quencher molecule, thereby causing fluorescence from the reporter molecule to appear.

The Taq-Man approach, illustrated in Figure 1, uses an oligonucleotide probe containing a reporter molecule - quencher molecule pair that specifically anneals to a region of a target polynucleotide "downstream", i.e. in the direction of extension of primer binding sites. The reporter molecule and quencher molecule are positioned on the probe sufficiently close to each other such that whenever the reporter molecule is excited, the energy of the excited state nonradiatively transfers to the quencher molecule where it either dissipates nonradiatively or is emitted at a different emission frequency than that of the reporter molecule. During strand extension by a DNA polymerase, the probe anneals to the template where it is digested by the 5'→3' exonuclease activity of the polymerase. As a result of the probe being digested, the reporter molecule is effectively separated from the quencher molecule such that the quencher molecule is no longer close enough to the reporter molecule to quench the reporter molecule's fluorescence. Thus, as more and more probes are digested during amplification, the number of reporter molecules in solution increases, thus resulting in an increasing number of unquenched reporter molecules which produce a stronger and stronger fluorescent signal.

Three main factors influence the utility of reporter-quencher molecule pair probes in hybridization and amplification assays. The first factor is the effectiveness of the quencher molecule on the probe to quench the reporter molecule. This first factor, herein designated "RQ", can be characterized by the ratio of the fluorescent emissions of the reporter molecule to the quencher molecule when the probe is not hybridized to a complementary polynucleotide. That is, RQ is the ratio

of the fluorescent emissions of the reporter molecule to the fluorescence of the quencher molecule when the oligonucleotide probe is in a single-stranded state. Influences on the value of RQ^- include, for example, the particular reporter and quencher molecules used, the spacing between the reporter and quencher molecules, nucleotide sequence-specific effects, and the degree of flexibility of structures, e.g., linkers, to which the reporter and quencher molecules are attached, and the presence of impurities. Wo *et al.*, *Anal. Biochem.*, 218: 1-13 (1994); and Clegg, *Meth. Enzymol.*, 211: 353-388 (1992). A related quantity RQ^+ , refers to the ratio of fluorescent emissions of the reporter molecule to the quencher molecule when the oligonucleotide probe is hybridized to a complementary polynucleotide.

A second factor is the efficiency of the probe to hybridize to a complementary polynucleotide. This second factor depends on the probe's melting temperature, T_m , the presence of a secondary structure in the probe or target polynucleotide, the annealing temperature, and other reaction conditions.

A third factor is the efficiency with which the DNA polymerase 5'→3' exonuclease activity cleaves the bound probe between the reporter molecule and quencher molecule. This efficiency depends on such factors as the proximity of the reporter or quencher to the 5' end of the probe, the "bulkiness" of the reporter or quencher, and the degree of complementarity between the probe and target polynucleotide. Lee *et al.*, *Nucleic Acids Research*, 21: 3761-3766 (1993).

Since quenching depends on the physical proximity of the reporter molecule to the quencher molecule, it was previously assumed that the quencher and reporter molecules must be attached to the probe such that the quencher molecule remains at all times within the maximum distance at which the quencher molecule can quench the

reporter molecule, this distance generally being a separation of about 6-16 nucleotides. Lee *et al.* Nucleic Acids Research. 21: 3761-3766 (1993); Mergny *et al.*, Nucleic Acids Research 22: 920-928 (1994); Cardullo *et al.*, Proc. Natl. Acad. Sci., 85: 8790-8794 (1988); Clegg *et al.*, Proc. Natl. Acad. Sci., 90: 2994-2998 (1993); and Ozaki *et al.*, Nucleic Acids Research, 20: 5205-5214 (1992). This short separation between the reporter molecule and the quencher molecule is typically achieved by attaching one member of the reporter-quencher pair to the 3' or 5' end of the probe and the other member to an internal base 6-16 nucleotides away.

There are at least two significant disadvantages associated with attaching a reporter or quencher molecule to an internal base. Attaching a reporter or quencher molecule to an internal nucleotide typically involves more difficult chemistry than the chemistry required to attach the molecule to a terminal nucleotide. In addition, attachment of a reporter or quencher molecule to an internal nucleotide can adversely affect the hybridization efficiency of the probe. Ward *et al.*, U. S. Patent 5,328,824; and Ozaki *et al.* Nucleic Acids Research, 20: 5205-5214 (1992).

A need currently exists for effective oligonucleotide probes containing a fluorescent reporter molecule and a quencher molecule for use in hybridization and nucleic acid amplification assays. Accordingly, a need exists for probes which exhibit distinguishable fluorescence characteristics when hybridized and not hybridized to a target nucleic acid sequence. A further need exists for probes where the reporter molecule and quencher molecule are positioned on the probe such that the quencher molecule can effectively quench the fluorescence of the reporter molecule. A further need exists for probes which are efficiently synthesized. Yet a further need exists for the reporter molecule and

quencher molecule to be positionable on the probe such that the reporter and quencher molecules do not adversely impact the hybridization efficiency of probe. These and further objectives are provided by the probes and methods of the present invention.

5

SUMMARY OF THE INVENTION

The present invention relates to an oligonucleotide probe which includes a fluorescent reporter molecule and a quencher molecule capable of quenching the fluorescence of the reporter molecule. According to the present invention, the oligonucleotide probe is constructed such that the probe exists in at least one single-stranded conformation when unhybridized where the quencher molecule is near enough to the reporter molecule to quench the fluorescence of the reporter molecule. The oligonucleotide probe also exists in at least one conformation when hybridized to a target polynucleotide where the quencher molecule is not positioned close enough to the reporter molecule to quench the fluorescence of the reporter molecule. By adopting these hybridized and unhybridized conformations, the reporter molecule and quencher molecule on the probe exhibit different fluorescence signal intensities when the probe is hybridized and unhybridized. As a result, it is possible to determine whether the probe is hybridized or unhybridized based on a change in the fluorescence intensity of the reporter molecule, the quencher molecule, or a combination thereof. In addition, because the probe can be designed such that the quencher molecule quenches the reporter molecule when the probe is not hybridized, the probe can be designed such that the reporter molecule exhibits limited fluorescence until the probe is either hybridized or digested.

According to the present invention, the fluorescence intensity of the reporter molecule is preferably greater than the fluorescence intensity of

the quencher molecule when the probe is hybridized to the target polynucleotide. The fluorescence intensity of the reporter molecule is more preferably at least about a factor of 3.5 greater than the fluorescence intensity of the quencher molecule when the probe is hybridized to the target polynucleotide.

The fluorescence intensity of the oligonucleotide probe hybridized to the target polynucleotide is also preferably at least about a factor of 6 greater than the fluorescence intensity of the oligonucleotide probe when not hybridized to the target polynucleotide.

The reporter molecule is preferably separated from the quencher molecule by at least about 15 nucleotides, more preferably at least about 18 nucleotides. The reporter molecule is preferably separated from the quencher molecule by between about 15 and 60 nucleotides, more preferably between about 18 and 30 nucleotides.

The reporter molecule is preferably attached to either the 3' or 5' terminal nucleotides of the probe. The quencher molecule is also preferably attached to either the 3' or 5' terminal nucleotides of the probe. More preferably, the reporter and quencher molecules are attached to the 3' and 5' or 5' and 3' terminal nucleotides of the probe respectively.

The reporter molecule is preferably a fluorescein dye and the quencher molecule is preferably a rhodamine dye.

In one embodiment, the oligonucleotide probe of the present invention is immobilized on a solid support. The oligonucleotide probe may be attached directly to the solid support, for example by attachment of the 3' or 5' terminal nucleotide of the probe to the solid support. More preferably, however, the probe is attached to the solid support by a linker. The linker serves to distance the probe from the solid support. The linker is most preferably at least 30 atoms in length, more preferably at least 50 atoms in length.

A wide variety of linkers are known in the art which may be used to attach the oligonucleotide probe to the solid support. The linker most preferably includes a functionalized polyethylene glycol because it does not significantly interfere with the hybridization of probe to the target oligonucleotide, is commercially available, soluble in both organic and aqueous media, easy to functionalize, and completely stable under oligonucleotide synthesis and post-synthesis conditions.

The linkages between the solid support, the linker and the probe are preferably not cleaved during removal of base protecting groups under basic conditions at high temperature. Examples of preferred linkages include carbamate and amide linkages.

The present invention also relates to the use of the oligonucleotide probe as a hybridization probe to detect target polynucleotides. Accordingly, the present invention relates to a hybridization assay for detecting the presence of a target polynucleotide in a sample. In one embodiment of the method, the hybridization probe is immobilized on a solid support.

According to the method, an oligonucleotide probe of the present invention is contacted with a sample of polynucleotides under conditions favorable for hybridization. The fluorescence signal of the reporter molecule before and after being contacted with the sample is compared. Since the reporter molecule on the probe exhibits a greater fluorescence signal when hybridized to a target sequence, an increase in the fluorescence signal after the probe is contacted with the sample indicates the hybridization of the probe to target sequences in the sample, thereby indicating the presence of target sequences in the sample. Quantification of the change in fluorescence intensity as a result of the probe being contacted with the sample can be used to quantify the amount of target sequences present in the sample.

66001-4545460

The present invention also relates to the use of the oligonucleotide probe for monitoring nucleic acid amplification. Accordingly, the present invention relates to a method for monitoring nucleic acid amplification by performing nucleic acid amplification on a target sequence using a nucleic acid polymerase having 5'- 3' nuclease activity, a primer capable of hybridizing to the target sequence and an oligonucleotide probe according to the present invention which is capable of hybridizing to the target sequence 3' relative to the primer. According to the method, the nucleic acid polymerase digests the oligonucleotide probe during amplification when it is hybridized to the target sequence, thereby separating the reporter molecule from the quencher molecule. As the amplification is conducted, the fluorescence of the reporter molecule is monitored, the generation of fluorescence corresponding to the occurrence of nucleic acid amplification. Accordingly, the amount of amplification performed can be quantified based on the change in fluorescence observed. It is noted that the fluorescence of the quencher molecule may also be monitored, either separately or in combination with the reporter molecule, to detect amplification.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates a method for real-time monitoring nucleic acid amplification utilizing a probe which is degraded by the 5' → 3' exonuclease activity of a nucleic acid polymerase.

Figure 2 illustrates a probe according to the present invention immobilized to a solid support in hybridized and unhybridized conformations.

DETAILED DESCRIPTION

5 The present invention relates to an oligonucleotide probe which includes a fluorescent reporter molecule and a quencher molecule capable of quenching the fluorescence of the reporter molecule. According to the present invention, the oligonucleotide probe is constructed such that the probe exists in at least one single-stranded conformation when unhybridized where the quencher molecule is near enough to the reporter molecule to quench the fluorescence of the reporter molecule. The oligonucleotide probe also exists in at least one conformation when 10 hybridized to a target polynucleotide such that the quencher molecule is not positioned close enough to the reporter molecule to quench the fluorescence of the reporter molecule. By adopting these hybridized and unhybridized conformations, the reporter molecule and quencher molecule on the probe exhibit different fluorescence signal intensities when the probe is hybridized and unhybridized. As a result, it is possible to 15 determine whether the probe is hybridized or unhybridized based on a change in the fluorescence intensity of the reporter molecule, the quencher molecule, or a combination thereof. In addition, because the probe can be designed such that the quencher molecule quenches the reporter molecule when the probe is not hybridized, the probe can be designed such that the reporter molecule exhibits limited fluorescence unless the probe is either 20 hybridized or digested.

25 According to the present invention, the fluorescence intensity of the reporter molecule is preferably greater than the fluorescence intensity of the quencher molecule when the probe is hybridized to the target polynucleotide. The fluorescence intensity of the reporter molecule is more preferably at least about a factor of 3.5 greater than the fluorescence intensity of the quencher molecule when the probe is hybridized to the target polynucleotide.

66801-15492460

The fluorescence intensity of the oligonucleotide probe hybridized to the target polynucleotide is also preferably at least about a factor of 6 greater than the fluorescence intensity of the oligonucleotide probe when not hybridized to the target polynucleotide.

5 The reporter molecule is preferably separated from the quencher molecule by at least about 15 nucleotides, more preferably at least about 18 nucleotides. The reporter molecule is preferably separated from the quencher molecule by between about 15 and 60 nucleotides, more preferably between about 18 and 30 nucleotides.

10 The reporter molecule is preferably attached to either the 3' or 5' terminal nucleotides of the probe. The quencher molecule is also preferably attached to either the 3' or 5' terminal nucleotides of the probe. More preferably, the reporter and quencher molecules are attached to the 3' and 5' or 5' and 3' terminal nucleotides of the probe respectively.

15 The reporter molecule is preferably a fluorescein dye and the quencher molecule is preferably a rhodamine dye.

20 In one embodiment, the oligonucleotide probe is attached to a solid support. As illustrated in Figure 2, when the probe is unhybridized, the probe is able to adopt at least one single-stranded conformation such that the quencher molecule is near enough to the reporter molecule to quench the fluorescence of the reporter molecule. As further illustrated in Figure 2, when the probe is hybridized to a target sequence, the probe adopts at least one conformation where the quencher molecule is not positioned close enough to the reporter molecule to quench the fluorescence of the reporter molecule. As a result, the fluorescence intensity of the reporter molecule increases when the probe hybridizes to a target sequence.

25 As illustrated in Figure 2, different probes may be attached to the solid support and may be used to simultaneously detect different target sequences in a sample. Reporter molecules having different fluorescence

wavelengths can be used on the different probes, thus enabling hybridization to the different probes to be separately detected.

Examples of preferred types of solid supports for immobilization of the oligonucleotide probe include controlled pore glass, glass plates, polystyrene, avidin coated polystyrene beads, cellulose, nylon, acrylamide gel and activated dextran. CPG, glass plates and high cross-linked polystyrene. These solid supports are preferred for hybridization and diagnostic studies because of their chemical stability, ease of functionalization and well defined surface area. Solid supports such as controlled pore glass (CPG, 500 Å, 1000 Å) and non-swelling high cross-linked polystyrene (1000 Å) are particularly preferred in view of their compatibility with oligonucleotide synthesis.

The oligonucleotide probe may be attached to the solid support in a variety of manners. For example, the probe may be attached to the solid support by attachment of the 3' or 5' terminal nucleotide of the probe to the solid support. More preferably, however, the probe is attached to the solid support by a linker which serves to distance the probe from the solid support. The linker is most preferably at least 30 atoms in length, more preferably at least 50 atoms in length.

The length and chemical stability of linker between solid support and the first 3' unit of oligonucleotides play an important role in efficient synthesis and hybridization of support bound oligonucleotides. The linker arm should be sufficiently long so that a high yield (>97%) can be achieved during automated synthesis. The required length of the linker will depend on the particular solid support used. For example, a six atom linker is generally sufficient to achieve a >97% yield during automated synthesis of oligonucleotides when high cross-linked polystyrene is used as the solid support. The linker arm is preferably at least 20 atoms long in order to

attain a high yield (>97%) during automated synthesis when CPG is used as the solid support.

Hybridization of a probe immobilized to a solid support generally requires that the probe be separated from the solid support by at least 30 atoms, more preferably at least 50 atoms. In order to achieve this separation, the linker generally includes a spacer positioned between the linker and the 3' nucleoside. For oligonucleotide synthesis, the linker arm is usually attached to the 3'-OH of the 3' nucleoside by an ester linkage which can be cleaved with basic reagents to free the oligonucleotide from the solid support.

A wide variety of linkers are known in the art which may be used to attach the oligonucleotide probe to the solid support. The linker may be formed of any compound which does not significantly interfere with the hybridization of the target sequence to the probe attached to the solid support. The linker may be formed of a homopolymeric oligonucleotide which can be readily added on to the linker by automated synthesis. Alternatively, polymers such as functionalized polyethylene glycol can be used as the linker. Such polymers are preferred over homopolymeric oligonucleotides because they do not significantly interfere with the hybridization of probe to the target oligonucleotide. Polyethylene glycol is particularly preferred because it is commercially available, soluble in both organic and aqueous media, easy to functionalize, and completely stable under oligonucleotide synthesis and post-synthesis conditions.

The linkages between the solid support, the linker and the probe are preferably not cleaved during removal of base protecting groups under basic conditions at high temperature. Examples of preferred linkages include carbamate and amide linkages.

The oligonucleotide probe of the present invention may be used as a hybridization probe to detect target polynucleotides. Accordingly, the

present invention relates to a hybridization assay for detecting the presence of a target polynucleotide in a sample. According to the method, an oligonucleotide probe of the present invention is contacted with a sample of nucleic acids under conditions favorable for hybridization. The fluorescence signal of the reporter molecule is measured before and after being contacted with the sample. Since the reporter molecule on the probe exhibits a greater fluorescence signal when hybridized to a target sequence, an increase in the fluorescence signal after the probe is contacted with the sample indicates the hybridization of the probe to target sequences in the sample and hence the presence of target sequences in the sample. Further, by quantifying the change in fluorescence intensity as a result of the probe being contacted with the sample, the amount of target sequences in the sample can be quantified.

According to one embodiment of the method, the hybridization probe is immobilized on a solid support. The oligonucleotide probe is contacted with a sample of nucleic acids under conditions favorable for hybridization. The fluorescence signal of the reporter molecule is measured before and after being contacted with the sample. Since the reporter molecule on the probe exhibits a greater fluorescence signal when hybridized to a target sequence, an increase in the fluorescence signal after the probe is contacted with the sample indicates the hybridization of the probe to target sequences in the sample. Immobilization of the hybridization probe to the solid support enables the target sequence hybridized to the probe to be readily isolated from the sample. In later steps, the isolated target sequence may be separated from the solid support and processed (e.g., purified, amplified) according to methods well known in the art depending on the particular needs of the researcher.

The oligonucleotide probe of the present invention may also be used as a probe for monitoring nucleic acid amplification. Accordingly, the

present invention relates to a method for monitoring nucleic acid amplification using an oligonucleotide probe according to the present invention which is capable of hybridizing to the target sequence 3' relative to an amplification primer. According to the method, nucleic acid amplification is performed on a target polynucleotide using a nucleic acid polymerase having 5'- 3' nuclease activity, a primer capable of hybridizing to the target polynucleotide, and an oligonucleotide probe according to the present invention capable of hybridizing to the target polynucleotide 3' relative to the primer. During amplification, the nucleic acid polymerase digests the oligonucleotide probe when it is hybridized to the target sequence, thereby separating the reporter molecule from the quencher molecule. As the amplification is conducted, the fluorescence of the reporter molecule is monitored, the generation of fluorescence corresponding to the occurrence of nucleic acid amplification.

Use of a reporter-quencher pair probe generally in conjunction with the amplification of a target polynucleotide, for example, by PCR, e.g., is described in many references, such as Innis *et al.*, editors, PCR Protocols (Academic Press, New York, 1989); Sambrook *et al.*, Molecular Cloning, Second Edition (Cold Spring Harbor Laboratory, New York, 1989), each of which are incorporated herein by reference. The binding site of the oligonucleotide probe is located between the PCR primers used to amplify the target polynucleotide. Preferably, PCR is carried out using Taq DNA polymerase, e.g., Amplitaq™ (Perkin-Elmer, Norwalk, CN), or an equivalent thermostable DNA polymerase, and the annealing temperature of the PCR is about 5-10°C below the melting temperature of the oligonucleotide probes employed.

Use of an oligonucleotide probe according to the present invention for monitoring nucleic acid amplification provides several advantages over the use of prior art reporter-quencher pair probes. For example, prior art

66001-1039

probes required that the reporter and quencher molecules be positioned on the probe such that the quencher molecule remained within a minimum quenching distance of the reporter molecule. However, by realizing that the probe need only be designed such that the probe be able to adopt a conformation where the quencher molecule is within a minimum quenching distance of the reporter molecule, a far wider array of probes are enabled. For example, dually labelled probes having the reporter and quencher molecules at the 5' and 3' ends can be designed. Such probes are far easier to synthesize than probes where the reporter molecule or the quencher molecule is attached to an internal nucleotide. Positioning of the reporter and quencher molecules on terminal nucleotides also enhances the hybridization efficiency of the probes.

As used in this application, the term "oligonucleotide", includes linear oligomers of natural or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, and the like; capable of specifically binding a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of basepairing, or the like. Usually monomers are linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g., 3-4, to several tens of monomeric units. Whenever an oligonucleotide is represented by a sequence of letters, such as "ATGCCTG", it will be understood that the nucleotides are in 5' → 3' order from left to right and that "A" denotes deoxyadenosine, "C" denotes deoxycytidine, "G" denotes deoxyguanosine, and "T" denotes thymidine, unless otherwise noted. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoranilidate, phosphoramidate, and the like. Generally, oligonucleotide probes of the invention will have a sufficient number of phosphodiester linkages adjacent to its 5' end so that the 5' → 3' exonuclease activity employed can efficiently

degrade the bound probe to separate the reporter and quencher molecules.

“Perfectly matched” in reference to a duplex means that the poly- or oligonucleotide strands making up the duplex form a double-stranded structure with one other such that every nucleotide in each strand undergoes Watson-Crick basepairing with a nucleotide in the other strand. The term also comprehends the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, and the like, that may be employed. Conversely, a “mismatch” in a duplex between a target polynucleotide and an oligonucleotide probe or primer means that a pair of nucleotides in the duplex fails to undergo Watson-Crick bonding.

As used in the application, “nucleoside” includes the natural nucleosides, including 2'-deoxy and 2'-hydroxyl forms, e.g., as described in Kornberg and Baker. DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992). “Analog” in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., described by Scheit, Nucleotide Analogs (John Wiley, New York, 1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990), or the like, with the only proviso that they are capable of specific hybridization. Such analogs include synthetic nucleosides designed to enhance binding properties, reduce degeneracy, increase specificity, and the like.

Oligonucleotide probes of the invention can be synthesized by a number of approaches, e.g., Ozaki *et al.*, Nucleic Acids Research, 20: 5205-5214 (1992); Agrawal *et al.*, Nucleic Acids Research, 18: 5419-5423 (1990); or the like. The oligonucleotide probes of the invention are conveniently synthesized on an automated DNA synthesizer, e.g., an Applied Biosystems, Inc. (Foster City, California) model 392 or 394 DNA/RNA Synthesizer, using standard chemistries, such as phosphoramidite chemistry, e.g., disclosed in the following references:

Beaucage and Iyer, Tetrahedron, 48: 2223-2311 (1992); Molko *et al.*, U. S. Patent 4,980,460; Koster *et al.*, U. S. Patent 4,725,677; Caruthers *et al.*, U. S. Patents 4,415,732; 4,458,066; and 4,973,679; and the like. Alternative chemistries, e.g., resulting in non-natural backbone groups, such as phosphorothioate, phosphoramidate, and the like, may also be employed provided that the hybridization efficiencies of the resulting oligonucleotides and/or cleavage efficiency of the exonuclease employed are not adversely affected.

Preferably, the oligonucleotide probe is in the range of 15-60 nucleotides in length. More preferably, the oligonucleotide probe is in the range of 18-30 nucleotides in length. The precise sequence and length of an oligonucleotide probe of the invention depends in part on the nature of the target polynucleotide to which it binds. The binding location and length may be varied to achieve appropriate annealing and melting properties for a particular embodiment. Guidance for making such design choices can be found in many of the above-cited references describing the "Taq-man" type of assays.

Preferably, the 3' terminal nucleotide of the oligonucleotide probe is blocked or rendered incapable of extension by a nucleic acid polymerase. Such blocking is conveniently carried out by the attachment of a reporter or quencher molecule to the terminal 3' carbon of the oligonucleotide probe by a linking moiety.

Preferably, reporter molecules are fluorescent organic dyes derivatized for attachment to the terminal 3' carbon or terminal 5' carbon of the probe via a linking moiety. Preferably, quencher molecules are also organic dyes, which may or may not be fluorescent, depending on the embodiment of the invention. For example, in a preferred embodiment of the invention, the quencher molecule is fluorescent. Generally whether the quencher molecule is fluorescent or simply releases the transferred energy

from the reporter by non-radiative decay, the absorption band of the quencher should substantially overlap the fluorescent emission band of the reporter molecule. Non-fluorescent quencher molecules that absorb energy from excited reporter molecules, but which do not release the energy radiatively, are referred to in the application as chromogenic molecules.

There is a great deal of practical guidance available in the literature for selecting appropriate reporter-quencher pairs for particular probes, as exemplified by the following references: Clegg (cited above); Wu *et al.* (cited above); Pesce *et al.*, editors, Fluorescence Spectroscopy (Marcel Dekker, New York, 1971); White *et al.*, Fluorescence Analysis: A Practical Approach (Marcel Dekker, New York, 1970); and the like. The literature also includes references providing exhaustive lists of fluorescent and chromogenic molecules and their relevant optical properties for choosing reporter-quencher pairs. e.g., Berlman, Handbook of Fluorescence Spectra of Aromatic Molecules, 2nd Edition (Academic Press, New York, 1971); Griffiths, Colour and Constitution of Organic Molecules (Academic Press, New York, 1976); Bishop, editor, Indicators (Pergamon Press, Oxford, 1972); Haugland, Handbook of Fluorescent Probes and Research Chemicals (Molecular Probes, Eugene, 1992) Pringsheim, Fluorescence and Phosphorescence (Interscience Publishers, New York, 1949); and the like. Further, there is extensive guidance in the literature for derivatizing reporter and quencher molecules for covalent attachment via common reactive groups that can be added to an oligonucleotide, as exemplified by the following references: Haugland (cited above); Ullman *et al.*, U. S. Patent 3,996,345; Khanna *et al.*, U. S. Patent 4,351,760; and the like.

Exemplary reporter-quencher pairs may be selected from xanthene dyes, including fluoresceins, and rhodamine dyes. Many suitable forms of these compounds are widely available commercially with substituents on

their phenyl moieties which can be used as the site for bonding or as the bonding functionality for attachment to an oligonucleotide. Another group of fluorescent compounds are the naphthylamines, having an amino group in the alpha or beta position. Included among such naphthylamino compounds are 1-dimethylaminonaphthyl-5-sulfonate, 1-anilino-8-naphthalene sulfonate and 2-p-touidiny-6-naphthalene sulfonate. Other dyes include 3-phenyl-7-isocyanatocoumarin, acridines, such as 9-isothiocyanatoacridine and acridine orange; N-(p-(2-benzoxazolyl)phenyl)maleimide; benzoxadiazoles, stilbenes, pyrenes, and the like.

Preferably, reporter and quencher molecules are selected from fluorescein and rhodamine dyes. These dyes and appropriate linking methodologies for attachment to oligonucleotides are described in many references, e.g., Khanna *et al.* (cited above); Marshall, *Histochemical J.*, 7: 299-303 (1975); Menchen *et al.*, U. S. Patent 5,188,934; Menchen *et al.*, European Patent Application 87310256.0; and Bergot *et al.*, International Application PCT/US90/05565. The latter four documents are hereby incorporated by reference.

There are many linking moieties and methodologies for attaching reporter or quencher molecules to the 5' or 3' termini of oligonucleotides, as exemplified by the following references: Eckstein, editor, *Oligonucleotides and Analogues: A Practical Approach* (IRL Press, Oxford, 1991); Zuckerman *et al.*, *Nucleic Acids Research*, 15: 5305-5321 (1987) (3' thiol group on oligonucleotide); Sharma *et al.*, *Nucleic Acids Research*, 19: 3019 (1991) (3' sulfhydryl); Giusti *et al.*, *PCR Methods and Applications*, 2: 223-227 (1993) and Fung *et al.*, U. S. Patent 4,757,141 (5' phosphoamino group via Aminolink™ II available from Applied Biosystems, Foster City, CA) Stabinsky, U. S. Patent 4,739,044 (3' aminoalkylphosphoryl group); Agrawal *et al.*, *Tetrahedron Letters*, 31:

1543-1546 (1990) (attachment via phosphoramidate linkages); Sproat *et al.*, Nucleic Acids Research, 15: 4837 (1987) (5' mercapto group); Nelson *et al.*, Nucleic Acids Research, 17: 7187-7194 (1989) (3' amino group); and the like.

5 Preferably, commercially available linking moieties are employed that can be attached to an oligonucleotide during synthesis, e.g., available from Clontech Laboratories (Palo Alto, CA).

10 Rhodamine and fluorescein dyes are also conveniently attached to the 5' hydroxyl of an oligonucleotide at the conclusion of solid phase synthesis by way of dyes derivatized with a phosphoramidite moiety, e.g., Woo *et al.*, U. S. Patent 5,231, 191; and Hobbs, Jr., U. S. Patent 4,997,928.

15 The following examples set forth probes and methods for using the probes according to the present invention. It is understood that the specific probes, probe constructs and steps of the methods described in these examples are not intended to be limiting. Further objectives and advantages of the present invention other than those set forth above will become apparent from the examples which are not intended to limit the scope of the present invention.

20 EXAMPLES

1. Synthesis of Oligonucleotide Probes

25 The following example describes the synthesis of the oligonucleotides shown in Table 1. Linker arm nucleotide ("LAN") phosphoramidite was obtained from Glen Research. Standard DNA phosphoramidites, 6-carboxyfluorescein ("6-FAM") phosphoramidite, 6-carboxytetramethylrhodamine succinimidyl ester ("TAMRA NHS ester"), and Phosphalink™ for attaching a 3' blocking phosphate were obtained

from Perkin-Elmer, Applied Biosystems Division. Oligonucleotide synthesis was performed on a model 394 DNA Synthesizer (Applied Biosystems). Primer and complement oligonucleotides were purified using Oligo Purification Cartridges (Applied Biosystems). Doubly labeled probes were synthesized with 6-FAM-labeled phosphoramidite at the 5' end, LAN replacing one of the T's in the oligonucleotide sequence, and Phosphalink™ at the 3' end. Following deprotection and ethanol precipitation, TAMRA NHS ester was coupled to the LAN-containing oligonucleotide in 250 mM Na-bicarbonate buffer (pH 9.0) at room temperature. Unreacted dye was removed by passage over a PD-10 Sephadex column. Finally, the doubly labeled probe was purified by preparative HPLC using standard protocols. Below, probes are named by designating the sequence from Table 1 and the position of the LAN-TAMRA moiety. For example, probe A1-7 has sequence of A1 with LAN-TAMRA at nucleoside position 7 from the 5' end.

Table 1. Sequences of oligonucleotides

Name	Type	Sequence
F119	primer	ACCCACAGGAACTGATCACCCTC [SEQ. ID. No.: 1]
R119	primer	ATGTCGCGTTCCGGCTGACGTTCTGC [SEQ. ID. No.: 2]
P2	probe	TCGCATTACTGATCGTTGCCAACCAGT _p [SEQ. ID. No.: 3]
P2C	complement	GTA CTGGTTGGCAACGATCAGTAATGCGATG [SEQ. ID. No.: 4]
P5	probe	CGGATTTGCIGGTATCTATGACAAGGAT _p [SEQ. ID. No.: 5]
P5C	complement	TTCATCCTTGTCATAGATACCAGCAAATCCG [SEQ. ID. No.: 6]
AFP	primer	TCACCCACACTGTGCCCATCTACGA [SEQ. ID. No.: 7]
ARP	primer	CAGCGGAACCGCTCATTGCCAATGG [SEQ. ID. No.: 8]
A1	probe	AIGCCCTCCCCCAIGCCAICCTIGCGI _p [SEQ. ID. No.: 9]
A1C	complement	AGACGCAGGATGGCATGGGGGAGGGCATA C [SEQ. ID. No.: 10]
A3	probe	CGCCCTGGACTTCGAGCAAGAGAT _p [SEQ. ID. No.: 11]
A3C	complement	CCATCTCTTGCTCGAAGTCCAGGGCGAC [SEQ. ID. No.: 12]
G1	probe	CAAGCTTCCCGTTCTCAGCCT [SEQ. ID. No.: 13]
G1C	complement	ACCGTCAAGGCTGAGAACGGGAAGCTTGTC [SEQ. ID. No.: 14]

Variable	Unit	Value
Age	Years	65.0
Sex	Male/Female	50/50
Weight	kg	70.0
Height	m	1.75
BMI	kg/m ²	22.2
Heart rate	beats/min	72.0
Blood pressure	mmHg	120/80
Glucose	mmol/L	5.0
Cholesterol	mmol/L	5.0
Triglycerides	mmol/L	1.0
Hemoglobin	g/dL	15.0
Hematocrit	%	45.0
White blood cells	10 ⁹ /L	7.0
Platelets	10 ⁹ /L	150.0
Neutrophils	%	60.0
Lymphocytes	%	35.0
Monocytes	%	5.0
Eosinophils	%	0.0
Basophils	%	0.0
Prothrombin time	sec	12.0
Partial thromboplastin time	sec	30.0
Fibrinogen	g/L	3.0
D-dimer	ng/mL	0.5
C-reactive protein	mg/L	1.0
Erythrocyte sedimentation rate	mm/hr	10.0
Urea nitrogen	mg/dL	10.0
Creatinine	mg/dL	1.0
BUN/Cr ratio	mg/dL	10.0
Calcium	mg/dL	10.0
Phosphorus	mg/dL	3.0
Magnesium	mg/dL	2.0
Sodium	mg/dL	140.0
Potassium	mg/dL	4.0
Chloride	mg/dL	100.0
Bicarbonate	mg/dL	24.0
Lactate	mg/dL	1.0
Ammonia	mg/dL	1.0
Bilirubin	mg/dL	1.0
Aspartate aminotransferase	U/L	10.0
Alanine aminotransferase	U/L	10.0
Gamma-glutamyl transferase	U/L	10.0
Alkaline phosphatase	U/L	10.0
Prothrombin time	sec	12.0
Partial thromboplastin time	sec	30.0
Fibrinogen	g/L	3.0
D-dimer	ng/mL	0.5
C-reactive protein	mg/L	1.0
Erythrocyte sedimentation rate	mm/hr	10.0
Urea nitrogen	mg/dL	10.0
Creatinine	mg/dL	1.0
BUN/Cr ratio	mg/dL	10.0
Calcium	mg/dL	10.0
Phosphorus	mg/dL	3.0
Magnesium	mg/dL	2.0
Sodium	mg/dL	140.0
Potassium	mg/dL	4.0
Chloride	mg/dL	100.0
Bicarbonate	mg/dL	24.0
Lactate	mg/dL	1.0
Ammonia	mg/dL	1.0
Bilirubin	mg/dL	1.0
Aspartate aminotransferase	U/L	10.0
Alanine aminotransferase	U/L	10.0
Gamma-glutamyl transferase	U/L	10.0
Alkaline phosphatase	U/L	10.0





Table 4.



2. Synthesis of Oligonucleotide Probes Attached To A Solid Support

Both high cross-linked polystyrene (1000 Å) and controlled pore glass (CPG) (500 Å) are used as solid support matrices. The functionalization of a spacer (compound 5) is illustrated in Table 2. The attachment of the spacer to polystyrene and CPG supports, and the labelling of the solid supports with TAMRA dye is shown in Tables 3 and 4 respectively.

Table 2 illustrates a reaction scheme for the synthesis of a spacer, compound 5, which is used to derivatize CPG and polystyrene supports. As shown in Table 2, N-Fmoc-ε-aminocaproic acid was reacted with *DL*-homoserine in presence of HOBT/HBTU/DIPEA (Knorr, et al., Tetrahedron Lett. 1989, 30, 1927) in DMF to give compound 2 in 65% yield. Compound 2 was reacted with dimethoxytrityl chloride in presence of DMAP in pyridine to give compound 3 in 72% yield after chromatography. Treatment of compound 3 with a large excess of PEG-diamine (Buckmann, et al., Biotech. Appl. Biochem. 1987, 9, 258) in presence of HOBT/HBTU/DIPEA in DMF afforded amine 4 in 60% yield. The amine 4 was then converted to succinate 5 by treating amine 4 with succinic anhydride/Et₃N/DMAP in CH₂Cl₂ in 90% yield. The succinate 5 was then attached to polystyrene and CPG support as illustrated in Tables 3 and 4 respectively without further purification.

As illustrated in Tables 3 and 4, succinate 5 was separately reacted with polystyrene and CPG support in presence of HOBT/HBTU/DIPEA in DMF to provide functionalized support 6 (5 µmol/g loading) and functionalized support 8 (15 µmol/g loading) respectively. The Fmoc group was removed from support bound spacer by treating supports 6 and 8 with 20% piperidine in DMF (Fields, et al., J. Peptide Res. 1990, 35, 161) to give amine which was reacted with TAMRA NHS ester to give TAMRA labeled supports 7 and 9 respectively. The polystyrene and CPG supports showed a final loading of 4.8 µmol/g and 14 µmol/g respectively by trityl cation assay.

Double labeled Taqman probe was synthesized using both TAMRA labeled supports 7 and 9, FastPhoramidites (User Bulletin Number 85, Perkin Elmer Corporation 1994) and FAM phosphoramidite (User Bulletin Number 78, Perkin Elmer Corporation 1994) in 40 nanomol scale. The support bound oligonucleotides were deprotected by treating with MeOH:t-BuNH₂:H₂O (1:1:2) at 65 °C for 3 hours (Woo, et al., U.S. Patent No. 5,231,191). Liquid was removed and the support containing probes were washed with H₂O:MeOH (3:1) and MeOH. The support was then dried under vacuum and used in a hybridization assay.

Experimental:

Compound 2: *N,N*-Diisopropylethylamine (1.1g, 1.48 mL, 8.52 mmol), 1-hydroxybenzotriazol (420 mg, 3.1 mmol) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (1.17 g, 3.1 mmol) were added to a stirred solution of Nfmoc-ε-aminocaproic acid (1 g, 2.84 mmol) in DMF (30 mL) at room temperature. After 15 min *DL*-homoserine (1.35 g, 11.36 mmol) was added to the reaction mixture. After 3 hours, DMF was removed under reduced pressure. The residue was dissolved in CHCl₃ (100 mL) and washed with 5% aqueous HCl (2 X 50 mL). The organic layer was dried over MgSO₄ and evaporated to give a thick oil which was triturated with ether to give a colorless solid (840 mg, 65%). The product was left under high vacuum for 24 hours and used in the next step without further purification.

Compound 3: 4,4'-Dimethoxytrityl chloride (484mg, 1.43 mmol) and 4-dimethylaminopyridine (25mg, 0.2 mmol) were added to a stirred solution of compound 2 (500mg, 1.1 mmol) in pyridine (15 mL) at room temperature under nitrogen atmosphere. After 14 hours, pyridine was removed and the residue was dissolved in CHCl₃ (70 mL). The organic layer was extracted with 5% aqueous citric acid (1 X 50 mL), H₂O (1 X 50 mL) and saturated brine (1 X 50

mL). The organic layer was dried over MgSO_4 and evaporated to give a yellow foam. The product was purified by a silica gel column eluting with CHCl_3 -MeOH gradient (0-10% MeOH). The appropriate fractions were combined and evaporated to give Compound 3 as a colorless foam (600 mg, 72%).

5

Compound 4: Poly(ethylene glycol) bis(2-aminoethyl ether) (3.16 g, 5.3 mmol), *N,N*-diisopropylethylamine (205 mg, 0.27 mL, 1.59 mmol), 1-hydroxybenzotriazol (78 mg, 0.58 mmol) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluonium hexafluorophosphate (220 mg, 0.58 mmol) were added to a stirred solution of compound 3 (400 mg, 0.53 mmol) in DMF (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. DMF was removed under reduced pressure and, the residue was dissolved in CHCl_3 (70 mL) and washed with H_2O (1 X 50 mL) and saturated brine (2 X 50 mL). The organic layer was dried over MgSO_4 and evaporated to give a thick oil. Compound 4 was purified by a silica gel column eluting with a CHCl_3 -MeOH gradient (5-15% MeOH) as a colorless glass (423 mg, 60%).

10

15

Compound 5: Succinic anhydride (22 mg, 0.22 mmol), Et_3N (23 mg, 0.31 μL , 0.22 mmol), 4-dimethylaminopyridine (14 mg, 0.11 mmol) were added to a solution of compound 4 (300 mg, 0.22 mmol) in CH_2Cl_2 (15 mL). The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with CHCl_3 (30 mL) and washed with 5% aqueous citric acid (1 X 50 mL) and saturated brine (2 X 50 mL). The organic layer was dried over MgSO_4 and evaporated to a colorless foam (284 mg, 90%) which was used for derivatization of the solid support without further purification.

20

25

Derivatization of Polystyrene support with TAMRA dye: High cross linked polystyrene (1000 Å, 10 $\mu\text{mol/g}$ amine loading, 1g, 10 μmol), was treated with compound 5 (17 mg, 12 μmol , 1-hydroxybenzotriazol (1.8 mg, 12 μmol), (2-(1H-

5 benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (4.8 mg, 12
μmol), *N,N*-diisopropylethylamine (6 μL, 30 μmol) in DMF (10 mL) on a wrist
action shaker for 4 hours at room temperature. The support was washed with
DMF (3 X 10 mL), CH₃CN (2 X 10 mL) and CH₂Cl₂ (1 X 10 mL) and dried under
10 high vacuum overnight. The ninhydrin assay showed 1 μmol/g amine left. The
trityl cation assay gave 5 μmol/g loading of compound 5. The support was
capped with acetic anhydride/lutidine in THF (10% solution, 5 mL) and 1-
methylimidazol in THF (16% solution, 5 mL) for 2 hours at room temperature.
The support was washed with CH₃CN (3 X 10 mL) and CH₂Cl₂ (1 X 10 mL). The
15 support was treated with 20% piperidine in DMF (3 X 10 mL) to remove the
Fmoc protecting group. The removal of the Fmoc group was monitored by
measuring UV of the solution at 302 nm. The support was washed with DMF (3
X 10 mL) and, then treated with TAMRA NHS ester (15 mg, 27 μmol) and Et₃N
(50 μmol) in DMF (10 mL) for 42 hours on a shaker. The support was washed
20 with DMF (3 X 10 mL) CH₃CN (2 X 10 mL) and CH₂Cl₂ (1 X 10 mL) and dried
under high vacuum for 24 hours. Ninhydrin test showed less than 0.5 μmol/g
amine left. The support was capped with acetic anhydride/lutidine in THF (10%
solution, 5 mL) and 1-methylimidazol in THF (16% solution, 5 mL) for 1 hour and
then washed with CH₃CN (3 X 10 mL), CH₂Cl₂ (2 X 10 mL) and dried under high
vacuum for 24 hour. The trityl cation assay showed a final loading of 4.8 μmol/g.

Derivatization of CPG support with TAMRA dye: A mixture of CPG (500 Å, 40
μmol/g amine loading, 500 mg, 20 μmol), compound 5 (31 mg, 22 μmol), 1-
hydroxybenzotriazol (5.9 mg, 22 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-
25 tetramethyluronium hexafluorophosphate (8.4 mg, 22 μmol), *N,N*-
diisopropylethylamine (10.4 μL, 60 μmol) in DMF (10 mL) was shaken on a wrist
action shaker for 4 hours at room temperature. The support was washed with
DMF (3 X 10 mL), CH₃CN (2 X 10 mL) and CH₂Cl₂ (1 X 10 mL) and dried under
high vacuum overnight. The ninhydrin assay showed 4 μmol/g amine left. The

trityl assay gave 15 $\mu\text{mol/g}$ loading of compound **5** on CPG support. The support was capped with acetic anhydride/lutidine in THF (10% solution, 5 mL) and 1-methylimidazol in THF (16% solution, 5 mL) for 2 hours at room temperature. The support was washed with CH_3CN (3 X 10 mL) and CH_2Cl_2 (1 X 10 mL). The support was treated with 20% piperidine in DMF (3 X 10 mL) to remove the Fmoc protecting group. Removal of the Fmoc group was monitored by measuring UV of the solution at 302 nm. The support was washed with DMF (3 X 10 mL). The support was then treated with TAMRA NHS ester (25 mg, 45 μmol) and Et_3N (90 μmol) in DMF (5 mL) for 42 hours on a shaker. The support was washed with DMF (3 X 10 mL), CH_3CN (2 X 10 mL) and CH_2Cl_2 (1 X 10 mL) and dried under high vacuum for 24 hours. Ninhydrin test showed less than 1 $\mu\text{mol/g}$ amine left. The support was capped with acetic anhydride/lutidine in THF (10% solution, 5 mL) and 1-methylimidazol in THF (16% solution, 5 mL) for 1 hour and then washed with CH_3CN (3 X 10 mL), CH_2Cl_2 (2 X 10 mL) and dried under high vacuum for 24 hours. The trityl cation assay showed a final loading of 14 $\mu\text{mol/g}$.

Synthesis of FAM and TAMRA Doubled Labeled Probes: Doubled dye labeled oligonucleotide probe were synthesized by using TAMRA labelled supports **7** and **9**. DNA FastPhosphoramidite and FAM amidite in 40 nmol scale. After completion of synthesis, supports containing probes were transferred to 4 mL glass vials and treated with a mixture of $\text{MeOH}:\text{t-BuNH}_2:\text{H}_2\text{O}$ (1:1:2) at 65 $^\circ\text{C}$ for 3 hours. Liquid was removed by a syringe and the support was washed with $\text{H}_2\text{O}:\text{MeOH}$ (3:1) and MeOH. The support was dried under vacuum and used in the hybridization assay.

3. Hybridization Assay Using Oligonucleotide Probe

A 295 basepair segment of exon 3 of human beta-actin gene (nucleotides 2141-2435 as disclosed in Nakajima-Iijima, S., Proc. Natl. Acad. Sci. USA 82:

6133-6137 (1985) can be amplified using 50 ul reactions that contain 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 4 mM MgCl₂, 300 nM primer AFP [SEQ. I.D. No. 7], 300 nM primer biotin-ARP [SEQ. I.D. No. 8 with biotin attached to the 5' end], 200 μM dATP, 200 μM dCTP, 200 μM dGTP, 200 μM TTP, and 1.25 units
5 AmpliTaq (Perkin-Elmer). The reactions are performed with (+ template) or without (no template) 20 ng human genomic DNA.

After thermal cycling at 50 °C (2 min); 95 °C (10 min); and 40 cycles of 95 °C (20 sec) followed by 60 °C (1 min), each sample is diluted by adding 200 μl Hybridization Buffer (5X SSC, 8% (v/v) formamide, 8% (v/v) Triton X- 100). The
10 resulting samples are transferred to a streptavidin-coated 96-well microtiter plate (Xenopore Corp., Saddle Brook, NJ) and incubated at 37 °C for 30 min in order to capture the amplified beta-actin DNA segment. Each well is then washed with 350 μl phosphate buffered saline/0.05% TWEEN-20. Any unbiotinylated DNA strands are removed by adding 100 μl 0.1 M NaOH / 1 mM EDTA, incubating at
15 room temperature for 5 min, and washing with 350 ul phosphate buffered saline/0.05% TWEEN-20. 50 ul of Hybridization Buffer containing 100 nM of probe A1-26 [SEQ. I.D. No. 9, nucleotides 1-26 (A1-26), labeled with reporter FAM and quencher TAMRA) is then added and incubate at 37 °C for 30 min.

Fluorescence is then measured at 518 nm and 582 nm using a
20 Perkin-Elmer TaqMan LS-50B System. The ΔRQ is then calculated as described in Example 5. The magnitude of ΔRQ indicates the level of hybridization of the A1-26 probe and thus is a measure of the amount of amplified beta-actin DNA segment captured in each well.

25
4. Hybridization Assay Using
Oligonucleotide Probe Attached To Solid Support

Three probe/solid support combinations were examined: A1-PS: A1
30 [SEQ. I.D. No. 9] attached to polystyrene support: A1-CPG: A1 [SEQ. I.D. No. 9]

attached to glass support; and G1-PS: G1 [SEQ. I.D. No. 13] attached to polystyrene support.

All three probes have FAM attached to the 5' end of the sequence and TAMRA attached to the 3' end. No template reactions were prepared by suspending each probe/solid support sample in 50 µl 1X PCR Buffer (10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3.5 mM MgCl₂). For plus template reactions, A1-PS and A1-CPG were suspended in 50 µl 1X PCR Buffer + 1 µM A1C; G1-PS was suspended in 50 µl 1X PCR Buffer + 1 µM G1C.

Reactions were incubated at 95 °C for 1 min, then allowed to cool slowly to room temperature. A portion of each suspension was placed on a microscope slide. Each sample was excited with 488 nm light and a fluorescence image was captured on a CCD array using either a 518 nm or 583 nm interference filter. The images were analyzed by finding a peak pixel value on the 518 nm image and then finding the 583 nm value for the same pixel. Pixel values were corrected by subtracting the background readings observed with buffer. Table 5 gives the results of fluorescence measurements of the indicated probes.

Table 5.

PROBE	518		582		RQ-	RQ+	ΔRQ
	no temp.	+temp.	no temp.	+temp.			
A1-PS	149	354	253	379	0.42	0.67	0.25
A1-CPG	494	437	1500	616	1.13	2.44	1.31
G1-PS	75	166	178	245	0.45	0.73	0.28

5. Method For Monitoring
PCR Amplification Using Oligonucleotide Probe

All PCR amplifications were performed in a Perkin-Elmer Thermocycler 9600 using 50 µl reactions that contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 200 µM dATP, 200 µM dCTP, 200 µM dGTP, 400 µM dUTP, 0.5 units AmpErase™ uracil N-glycosylase (Perkin-Elmer), and 1.25 units AmpliTaq™ (Perkin-Elmer). A 295 basepair segment of exon 3 of human β-actin gene (nucleotides 2141-2435 disclosed by Nakajima-Iijima. S., Proc. Natl. Acad. Sci. USA 82: 6133-6137 (1985) was amplified using the AFP and ARP primers listed below. The amplification reactions contained 4 mM MgCl₂, 20 ng human genomic DNA, 50 nM A1 or A3 probe, and 300 nM of each primer. Thermal regimen was 50 °C (2 min); 95 °C (10 min); 40 cycles of 95 °C (20 sec); 60 °C (1 min); and hold at 72 °C. A 515 basepair segment was amplified from a plasmid that consists of a segment of λ DNA (nucleotides 32, 220-32, 747) inserted into the Sma I site of vector pUC119. These reactions contained 3.5 mM MgCl₂, 1 ng plasmid DNA, 50 nM P2 or P5 probe, 200 nM primer F119, and 200 nM primer R119. The thermal regimen was 50 °C (2 min); 95 °C (10 min); 25 cycles of 95 °C (20 sec), 57 °C (1 min); and hold at 72 °C.

For each amplification reaction, 40 µl was transferred to an individual well of a white 96-well microtiter plate (Perkin-Elmer). Fluorescence was measured on a Perkin-Elmer TaqMan™ LS-50B System, which consists of a luminescence spectrometer with a plate reader assembly, a 485 nm excitation filter, and a 515 nm emission filter. Excitation was carried out at 488 nm using a 5 nm slit width. Emission was measured at 518 nm for 6-FAM (the reporter, or R Value) and 582 nm for TAMRA (the quencher, or Q value) using a 10 nm slit width. In order to determine the increase in reporter emission that is due to cleavage of the probe during PCR, three normalizations are applied to the raw emission data. First, emission intensity of a buffer blank is subtracted for each wavelength. Second, emission intensity of the reporter is divided by the emission intensity of the quencher to give an RQ ratio for each reaction tube. This normalizes for well-to-

well variation in probe concentration and fluorescence measurement. Finally, ΔRQ is calculated by subtracting the RQ value of the no template control (RQ^-) from the RQ value for the complete reaction including a template (RQ^+).

Three pairs of probes were tested in PCR assays. For each pair, one probe has TAMRA attached to an internal nucleotide and the other has TAMRA attached to the 3' end nucleotide. Results are shown in Table 6. For all three sets, the probe with the 3' quencher exhibits a ΔRQ value that is considerable higher than for the probe with the internal quencher.

Table 6.

PROBE	518		582		RQ-	RQ+	ΔRQ
	no temp.	+temp.	no temp.	+temp.			
A3-6	34.06	50.1	73.78	70.8	0.5	0.71	0.25
A3-24	58.85	202	69.66	78.8	0.8	2.57	1.72
P2-7	67.58	341	85.78	87.9	0.8	3.89	3.1
P2-27	124.6	722	152.6	118	0.8	6.1	5.28
P5-10	77.32	156	75.41	67	1	2.33	1.3
P5-28	73.23	507	106.6	96.3	0.7	5.28	4.59

Table 7. Fluorescence In Single And Double-stranded States.

Probe	518		582		RQ	
	ss	ds	ss	ds	ss	ds
P2-7	63.81	84.07	96.52	142.97	0.66	0.59
P2-27	92.31	557.53	165.13	89.47	0.56	6.23
P5-10	266.30	366.37	437.97	491.00	0.61	0.75
P5-28	51.91	782.80	141.20	154.07	0.37	5.08
A1-7	18.40	60.45	105.53	218.83	0.17	0.28
A1-26	87.75	734.37	90.91	118.57	0.97	6.19
A3-6	44.77	104.80	90.80	177.87	0.49	0.59
A3-24	45.57	857.57	100.15	191.43	0.46	3.47

Table 7 gives the results of fluorescence measurements of the indicated probes in single and double-stranded states. For probes having reporter and quencher at opposite ends of the oligonucleotide, hybridization caused a dramatic increase in RQ.

The foregoing description of a preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. It is intended that the scope of the invention be defined by the following claims and their equivalents.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Perkin-Elmer Corporation,
Applied Biosystems Division

5 (ii) TITLE OF INVENTION: HYBRIDIZATION ASSAY USING
SELF-QUENCHING FLUORESCENCE PROBE

(iii) NUMBER OF SEQUENCES: 14

(iv) CORRESPONDENCE ADDRESS:

10 (A) ADDRESSEE: David J. Weitz,
Haynes & Davis
(B) STREET: 2180 Sand Hill Road, Suite 310
(C) CITY: Menlo Park
(D) STATE: California
(E) COUNTRY: USA
15 (F) ZIP: 94025-6935

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5 inch diskette
(B) COMPUTER: IBM compatible
20 (C) OPERATING SYSTEM: Microsoft Windows 3.1/DOS
5.0
(D) SOFTWARE: Wordperfect for windows 6.0,
ASCII (DOS) TEXT format

25 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 08/340,558

(B) FILING DATE: 16-NOV-94

5 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: David J. Weitz

(B) REGISTRATION NUMBER: 38,362

(C) REFERENCE/DOCKET NUMBER: PELM4264CIP2

10 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (415) 233-0188

(B) TELEFAX: (415) 233-1129

(2) INFORMATION FOR SEQ ID NO: 1:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ACCCACAGGA ACTGATCACC ACTC

24

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 26 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ATGTCGCGTT CCGGCTGACG TTCTGC

26

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 27 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TCGCATTACT GATCGTTGCC AACCAGT

27

(2) INFORMATION FOR SEQ ID NO: 4

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 31 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4

20 GTACTGGTTG GCAACGATCA GTAATGCGAT G

31

(2) INFORMATION FOR SEQ ID NO: 5

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 28 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5

CGGATTTGCT GGTATCTATG ACAAGGAT

28

(2) INFORMATION FOR SEQ ID NO: 6

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6

TTCATCCTTG TCATAGATAC CAGCAAATCC G

31

(2) INFORMATION FOR SEQ ID NO: 7

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7

TCACCCACAC TGTGCCCATC TACGA

25

(2) INFORMATION FOR SEQ ID NO: 8

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8

CAGCGGAACC GCTCATTGCC AATGG

25

(2) INFORMATION FOR SEQ ID NO: 9

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9

ATGCCCTCCC CCATGCCATC CTGCGT 26

(2) INFORMATION FOR SEQ ID NO: 10

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 30 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10

15 AGACGCAGGA TGGCATGGGG GAGGGCATACT 30

(2) INFORMATION FOR SEQ ID NO: 11

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 24 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11

CGCCCTGGAC TTCGAGCAAG AGAT 24

25

(2) INFORMATION FOR SEQ ID NO: 12

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 nucleotides
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12

CCATCTCTTG CTCGAAGTCC AGGGCGAC

28

5

(2) INFORMATION FOR SEQ ID NO: 13

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: nucleotides

(B) TYPE: nucleic acid

10

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13

CAAGCTTCCC GTTCTCAGCC T

21

15

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14

ACCGTCAAGG CTGAGAACGG GAAGCTTGTC

30

What is claimed is:

1 1. A method for detecting nucleic acid target sequences in a sample
2 comprising:

3 contacting a sample of nucleic acids with an oligonucleotide probe
4 under conditions favorable for hybridization, the oligonucleotide probe having
5 a sequence at least partially complementary to a target nucleic acid sequence
6 to be detected, the oligonucleotide probe including a fluorescent reporter
7 molecule and a quencher molecule capable of quenching the fluorescence of
8 said reporter molecule, said oligonucleotide probe existing in at least one
9 single-stranded conformation when unhybridized where said quencher
10 molecule quenches the fluorescence of said reporter molecule, said
11 oligonucleotide probe existing in at least one conformation when hybridized to
12 said target polynucleotide where the fluorescence intensity of said reporter
13 molecule when said oligonucleotide probe is hybridized to said target
14 polynucleotide is greater than the fluorescence intensity of said reporter
15 molecule when said oligonucleotide probe is not hybridized to said target
16 polynucleotide;

17 and

18 monitoring the fluorescence of said reporter molecule, an increase in the
19 fluorescence intensity of the reporter molecule indicating the presence of the
20 target sequence.

1 2. The method according to claim 1 wherein the fluorescence
2 intensity of said reporter molecule when said oligonucleotide probe is hybridized
3 to said target polynucleotide is at least about a factor of 6 greater than the
4 fluorescence intensity of said said reporter molecule when said oligonucleotide
5 probe is not hybridized to said target polynucleotide.

1 3. The method according to claim 1 wherein said reporter molecule is
2 separated from said quencher molecule by at least about 15 nucleotides.

1 4. The method according to claim 3 wherein said reporter molecule is
2 separated from said quencher molecule by between about 15 and 60
3 nucleotides.

1 5. The method according to claim 1 wherein said reporter molecule is
2 separated from said quencher molecule by at least about 18 nucleotides.

1 6. The method according to claim 5 wherein said reporter molecule is
2 separated from said quencher molecule by between about 18 and 30
3 nucleotides.

1 7. The method according to claim 1 wherein the reporter molecule is
2 attached to a 3' terminal nucleotide of the probe.

1 8. The method according to claim 7 wherein the quencher molecule is
2 attached to a 5' terminal nucleotide of the probe.

1 9. The method according to claim 1 wherein the reporter molecule is
2 attached to a 5' terminal nucleotide of the probe.

1 10. The method according to claim 9 wherein the quencher molecule is
2 attached to a 3' terminal nucleotide of the probe.

1 11. The method according to claim 1 wherein the quencher molecule is
2 attached to a 3' terminal nucleotide of the probe.

1 12. The method according to claim 1 wherein the quencher molecule is
2 attached to a 5' terminal nucleotide of the probe.

1 13. The method according to claim 1 wherein said nucleic acid
2 polymerase is a thermostable nucleic acid polymerase.

1 14. The method according to claim 1 wherein said reporter molecule is
2 a fluorescein dye and said quencher molecule is a rhodamine dye.

1 15. A method for detecting nucleic acid target sequences in a sample
2 comprising:

3 contacting a sample of nucleic acids with an oligonucleotide probe
4 under conditions favorable for hybridization, the oligonucleotide probe having
5 a sequence at least partially complementary to a target nucleic acid sequence
6 to be detected, the oligonucleotide probe including a fluorescent reporter
7 molecule and a fluorescent quencher molecule capable of quenching the
8 fluorescence of said reporter molecule, said oligonucleotide probe existing in
9 at least one single-stranded conformation when unhybridized where said
10 quencher molecule quenches the fluorescence of said reporter molecule, said
11 oligonucleotide probe existing in at least one conformation when hybridized to
12 said target polynucleotide where the fluorescence of said reporter molecule is
13 unquenched, the fluorescence intensity of said reporter molecule being
14 greater than the fluorescence intensity of said quencher molecule when said
15 probe is hybridized to said target polynucleotide;

16 and

17 monitoring the fluorescence of said reporter molecule, an increase in the
18 fluorescence intensity of the reporter molecule indicating the presence of the
19 target sequence.

1 16. The method according to claim 15 wherein the fluorescence
2 intensity of said reporter molecule is at least about a factor of 3.5 greater than
3 the fluorescence intensity of said quencher molecule when said probe is
4 hybridized to said target polynucleotide.

1 17. A method for detecting nucleic acid target sequences in a sample
2 comprising:
3 contacting a sample of nucleic acids with an oligonucleotide probe
4 under conditions favorable for hybridization, the oligonucleotide probe having
5 a sequence at least partially complementary to a target nucleic acid sequence
6 to be detected, the oligonucleotide probe including a fluorescent reporter
7 molecule and a quencher molecule capable of quenching the fluorescence of
8 said reporter molecule, said oligonucleotide probe existing in at least one
9 single-stranded conformation when unhybridized where said quencher
10 molecule quenches the fluorescence of said reporter molecule, said
11 oligonucleotide probe existing in at least one conformation when hybridized to
12 said target polynucleotide where the fluorescence of said reporter molecule is
13 unquenched, the ratio of the fluorescence intensities of said reporter molecule
14 to said quencher molecule when said probe is hybridized to said target
15 polynucleotide is greater than the ratio of the fluorescence intensities of said
16 reporter molecule to said quencher molecule when said probe is single-
17 stranded;
18 and
19 monitoring the fluorescence of said reporter molecule, an increase in the
20 fluorescence intensity of the reporter molecule indicating the presence of the
21 target sequence.

1 18. The method according to claim 17 wherein the ratio of the
2 fluorescence intensities of said reporter molecule to said quencher molecule

1 when said probe is hybridized to said target polynucleotide is at least about a
2 factor of 6 greater than the ratio of the fluorescence intensities of said reporter
3 molecule to said quencher molecule when said probe is single-stranded.

1 19. A method for detecting nucleic acid target sequences in a sample
2 comprising:

3 contacting a sample of nucleic acids with an oligonucleotide probe
4 attached to a solid support under conditions favorable for hybridization, the
5 oligonucleotide probe having a sequence at least partially complementary to a
6 target nucleic acid sequence to be detected, the oligonucleotide probe
7 including a fluorescent reporter molecule and a quencher molecule capable of
8 quenching the fluorescence of said reporter molecule, said oligonucleotide
9 probe existing in at least one single-stranded conformation when
10 unhybridized where said quencher molecule quenches the fluorescence of
11 said reporter molecule, said oligonucleotide probe existing in at least one
12 conformation when hybridized to said target polynucleotide where the
13 fluorescence intensity of said reporter molecule when said oligonucleotide
14 probe is hybridized to said target polynucleotide is greater than the
15 fluorescence intensity of said reporter molecule when said oligonucleotide
16 probe is not hybridized to said target polynucleotide;

17 and

18 monitoring the fluorescence of said reporter molecule, an increase in the
19 fluorescence intensity of the reporter molecule indicating the presence of the
20 target sequence.

1 20. The method according to claim 19 wherein the fluorescence
2 intensity of said reporter molecule when said oligonucleotide probe is hybridized
3 to said target polynucleotide is at least about a factor of 6 greater than the

1 fluorescence intensity of said reporter molecule when said oligonucleotide probe
2 is not hybridized to said target polynucleotide.

1 21. The method according to claim 19 wherein said reporter molecule
2 is separated from said quencher molecule by at least about 15 nucleotides.

1 22. The method according to claim 21 wherein said reporter molecule
2 is separated from said quencher molecule by between about 15 and 60
3 nucleotides.

1 23. The method according to claim 19 wherein said reporter molecule
2 is separated from said quencher molecule by at least about 18 nucleotides.

1 24. The method according to claim 23 wherein said reporter molecule
2 is separated from said quencher molecule by between about 18 and 30
3 nucleotides.

1 25. The method according to claim 19 wherein the reporter molecule is
2 attached to a 3' terminal nucleotide of the probe.

1 26. The method according to claim 25 wherein the quencher molecule
2 is attached to a 5' terminal nucleotide of the probe.

1 27. The method according to claim 19 wherein the reporter molecule is
2 attached to a 5' terminal nucleotide of the probe.

1 28. The method according to claim 27 wherein the quencher molecule
2 is attached to a 3' terminal nucleotide of the probe.

1 29. The method according to claim 19 wherein the quencher molecule
2 is attached to a 3' terminal nucleotide of the probe.

1 30. The method according to claim 19 wherein the quencher molecule
2 is attached to a 5' terminal nucleotide of the probe.

1 31. The method according to claim 19 wherein said reporter molecule
2 is a fluorescein dye and said quencher molecule is a rhodamine dye.

1 32. The method according to claim 19 wherein the probe is attached to
2 the solid support by a linker.

1 33. The method according to claim 32 wherein the linker separates the
2 probe from the solid support by at least 30 atoms.

1 34. The method according to claim 33 wherein the linker separates the
2 probe from the solid support by at least 50 atoms.

1 35. The method according to claim 32 wherein the linker is a
2 functionalized polyethylene glycol.

1 36. The method according to claim 35 wherein the linker is a
2 polynucleotide.

1 37. A method for detecting nucleic acid target sequences in a sample
2 comprising:
3 contacting a sample of nucleic acids with an oligonucleotide probe
4 attached to a solid support under conditions favorable for hybridization, the
5 oligonucleotide probe having a sequence at least partially complementary to a

target nucleic acid sequence to be detected, the oligonucleotide probe including a fluorescent reporter molecule and a fluorescent quencher molecule capable of quenching the fluorescence of said reporter molecule, said oligonucleotide probe existing in at least one single-stranded conformation when unhybridized where said quencher molecule quenches the fluorescence of said reporter molecule, said oligonucleotide probe existing in at least one conformation when hybridized to said target polynucleotide where the fluorescence of said reporter molecule is unquenched. the fluorescence intensity of said reporter molecule being greater than the fluorescence intensity of said quencher molecule when said probe is hybridized to said target polynucleotide;

and

monitoring the fluorescence of said reporter molecule, an increase in the fluorescence intensity of the reporter molecule indicating the presence of the target sequence.

38. The method according to claim 37 wherein the fluorescence intensity of said reporter molecule is at least about a factor of 3.5 greater than the fluorescence intensity of said quencher molecule when said probe is hybridized to said target polynucleotide.

39. A method for detecting nucleic acid target sequences in a sample comprising:

contacting a sample of nucleic acids with an oligonucleotide probe attached to a solid support under conditions favorable for hybridization, the oligonucleotide probe having a sequence at least partially complementary to a target nucleic acid sequence to be detected, the oligonucleotide probe including a fluorescent reporter molecule and a fluorescent quencher molecule capable of quenching the fluorescence of said reporter molecule,

said oligonucleotide probe existing in at least one single-stranded conformation when unhybridized where said quencher molecule quenches the fluorescence of said reporter molecule, said oligonucleotide probe existing in at least one conformation when hybridized to said target polynucleotide where the fluorescence of said reporter molecule is unquenched, the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said probe is hybridized to said target polynucleotide is greater than the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said probe is single-stranded;

and

monitoring the fluorescence of said reporter molecule, an increase in the fluorescence intensity of the reporter molecule indicating the presence of the target sequence.

40. The method according to claim 39 wherein the the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said probe is hybridized to said target polynucleotide is at least about a factor of 6 greater than the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said probe is single-stranded.


HYBRIDIZATION ASSAY USING
SELF-QUENCHING FLUORESCENCE PROBE

Inventors: Kenneth J. Livak, Susan J. A. Flood,
Jeffrey Maramaro and Khairuzzaman Bashar Mullah


ABSTRACT

A hybridization assay is provided which uses an oligonucleotide probe which includes a fluorescent reporter molecule and a quencher molecule capable of quenching the fluorescence of the reporter molecule. The oligonucleotide probe is constructed such that the probe exists in at least one single-stranded conformation when unhybridized where the quencher molecule is near enough to the reporter molecule to quench the fluorescence of the reporter molecule. The oligonucleotide probe also exists in at least one conformation when hybridized to a target polynucleotide where the quencher molecule is not positioned close enough to the reporter molecule to quench the fluorescence of the reporter molecule. By adopting these hybridized and unhybridized conformations, the reporter molecule and quencher molecule on the probe exhibits different fluorescence signal intensities when the probe is hybridized and unhybridized. As a result, it is possible to determine whether the probe is hybridized or unhybridized based on a change in the fluorescence intensity of the reporter molecule, the quencher molecule, or a combination thereof. In addition, because the probe can be designed such that the quencher molecule quenches the reporter molecule when the probe is not hybridized, the probe can be designed such that the reporter molecule exhibits limited fluorescence until the probe is either hybridized or digested.


Polymerization



Strand displacement



Cleavage



Polymerization completed




FIG. 1




FIG.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Kenneth J. Livak et al.) Group Art Unit: Unassigned
Application No. Unassigned) Examiner: Unassigned
Filed: Herewith (November 8, 1999))
For: HYBRIDIZATION ASSAY USING SELF-)
QUENCHING FLUORESCENCE PROBE)

STATEMENT UNDER 37 C.F.R. 1.10

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

I hereby certify that the attached patent application is being deposited with sufficient postage with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail Label No. EL324593567US, on November 8, 1999, addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

By: David J. Weitz
David J. Weitz
Registration No. 38,362

650 Page Mill Road
Palo Alto, California 94304
(650) 493-9300

November 8, 1999

Parameter	Unit	Value
1. α	deg	10.0
2. β	deg	10.0
3. γ	deg	10.0
4. δ	deg	10.0
5. ϵ	deg	10.0
6. ζ	deg	10.0
7. η	deg	10.0
8. θ	deg	10.0
9. ϕ	deg	10.0
10. χ	deg	10.0
11. ψ	deg	10.0
12. ω	deg	10.0
13. ν	deg	10.0
14. μ	deg	10.0
15. λ	deg	10.0
16. κ	deg	10.0
17. ι	deg	10.0
18. \hbar	deg	10.0
19. g	deg	10.0
20. f	deg	10.0
21. e	deg	10.0
22. d	deg	10.0
23. c	deg	10.0
24. b	deg	10.0
25. a	deg	10.0
26. z	deg	10.0
27. y	deg	10.0
28. x	deg	10.0
29. w	deg	10.0
30. v	deg	10.0
31. u	deg	10.0
32. t	deg	10.0
33. s	deg	10.0
34. r	deg	10.0
35. q	deg	10.0
36. p	deg	10.0
37. o	deg	10.0
38. n	deg	10.0
39. m	deg	10.0
40. l	deg	10.0
41. k	deg	10.0
42. j	deg	10.0
43. i	deg	10.0
44. h	deg	10.0
45. g	deg	10.0
46. f	deg	10.0
47. e	deg	10.0
48. d	deg	10.0
49. c	deg	10.0
50. b	deg	10.0
51. a	deg	10.0
52. z	deg	10.0
53. y	deg	10.0
54. x	deg	10.0
55. w	deg	10.0
56. v	deg	10.0
57. u	deg	10.0
58. t	deg	10.0
59. s	deg	10.0
60. r	deg	10.0
61. q	deg	10.0
62. p	deg	10.0
63. o	deg	10.0
64. n	deg	10.0
65. m	deg	10.0
66. l	deg	10.0
67. k	deg	10.0
68. j	deg	10.0
69. i	deg	10.0
70. h	deg	10.0
71. g	deg	10.0
72. f	deg	10.0
73. e	deg	10.0
74. d	deg	10.0
75. c	deg	10.0
76. b	deg	10.0
77. a	deg	10.0
78. z	deg	10.0
79. y	deg	10.0
80. x	deg	10.0
81. w	deg	10.0
82. v	deg	10.0
83. u	deg	10.0
84. t	deg	10.0
85. s	deg	10.0
86. r	deg	10.0
87. q	deg	10.0
88. p	deg	10.0
89. o	deg	10.0
90. n	deg	10.0
91. m	deg	10.0
92. l	deg	10.0
93. k	deg	10.0
94. j	deg	10.0
95. i	deg	10.0
96. h	deg	10.0
97. g	deg	10.0
98. f	deg	10.0
99. e	deg	10.0
100. d	deg	10.0

24

26

27

31

28

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6

TTCATCCTTG TCATAGATAC CAGCAAATCC G

31

(2) INFORMATION FOR SEQ ID NO: 7

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7

TCACCCACAC TGTGCCCATC TACGA

25

(2) INFORMATION FOR SEQ ID NO: 8

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8

CAGCGGAACC GCTCATTGCC AATGG

25

(2) INFORMATION FOR SEQ ID NO: 9

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9

ATGCCCTCCC CCATGCCATC CTGCGT

26

(2) INFORMATION FOR SEQ ID NO: 10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 nucleotides
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10

AGACGCAGGA TGGCATGGGG GAGGGCATAC

30

(2) INFORMATION FOR SEQ ID NO: 11

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11

CGCCCTGGAC TTCGAGCAAG AGAT

24

(2) INFORMATION FOR SEQ ID NO: 12

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12

CCATCTCTTG CTCGAAGTCC AGGGCGAC

28

(2) INFORMATION FOR SEQ ID NO: 13

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13

CAAGCTTCCC GTTCTCAGCC T

21

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 nucleotides

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14

ACCGTCAAGG CTGAGAACGG GAAGCTTGTC

30

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application) PATENT APPLICATION
)
Inventor(s): Livak, et al.)
)
Application No.: 08/558,303)
)
Filed: November 15, 1995)
)
Title: HYBRIDIZATION ASSAY USING)
SELF-QUENCHING FLUORESCENCE PROBE)

DECLARATION FOR PATENT APPLICATION
(CONTINUATION-IN-PART)

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if one name is listed below), first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HYBRIDIZATION ASSAY USING SELF-QUENCHING FLUORESCENCE PROBE

the specification of which (check applicable ones):

___ is attached hereto;

X was filed with the above-identified "Filed" date and "SC/Serial No."

___ was amended on (or amended through) .

x The present application is a continuation-in-part of Prior Application, Application No. 08/340,558, filed: November 16, 1994 and may be considered to disclose and claim subject matter in addition to that disclosed in the Prior Application, and I hereby claim the benefit of 35 U.S.C. Section 120.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose information which is material to the examination of the application in accordance with Title 37, Code of Federal Regulations, §1.56, including information which became available between the filing date of the Prior Application and the national or PCT international filing date of the present application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

(1) Full name of sole
or first inventor: Kenneth J. Livak

(1) Residence: 1148 Polk Lane
San Jose, CA
95117

(1) Post Office Address: Same as Above

(1) Citizenship: United States of America

(1) Inventor's signature: Kenneth J. Livak

(1) Date: 2/22/96

(2) Full name of second
joint inventor: Susan J.A. Flood

(2) Residence: 42931 Peachwood Street
Fremont, CA
94538

(2) Post Office Address: Same as Above

(2) Citizenship: United States of America

(2) Inventor's signature: Susan J. Flood

(2) Date: 2/21/96

(3) Full name of third
joint inventor: Jeffrey Mamoro

(3) Residence: 15154 E. Wesley Avenue
Aurora, CO
80014

(3) Post Office Address: Same as Above

(3) Citizenship: United States of America

(3) Inventor's signature: _____

(3) Date: _____

(1) Full name of sole
or first inventor: Kenneth J. Livak

(1) Residence: 1148 Polk Lane
San Jose, CA
95117

(1) Post Office Address: Same as Above

(1) Citizenship: United States of America

(1) Inventor's signature: _____

(1) Date: _____

(2) Full name of second
joint inventor: Susan J.A. Flood

(2) Residence: 42931 Peachwood Street
Fremont, CA
94538

(2) Post Office Address: Same as Above

(2) Citizenship: United States of America

(2) Inventor's signature: _____

(2) Date: _____

(3) Full name of third
joint inventor: Jeffrey ~~Marmore~~ Marmaro

(3) Residence: 15154 E. Wesley Avenue
Aurora, CO
80014

(3) Post Office Address: Same as Above

(3) Citizenship: United States of America

(3) Inventor's signature: *JJM Marmaro*

(3) Date: 2-22-96

(4) Full name of fourth
joint inventor: Khairuzzaman Bashar Mullah

(4) Residence: 32804 Regents Blvd.
Union City, CA
94587

(4) Post Office Address: Same as Above

(4) Citizenship: Bangladesh

(4) Inventor's signature: *KB Mullah*

(4) Date: 2/21/96

66011 45488-100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

IN RE PATENT APPLICATION OF)	
)	Examiner: Not Yet Assigned
Perkin-Elmer Corporation)	
)	Group Art Unit: Not Yet Assigned
Application No. 08/558,303)	
)	
Filing Date: November 15, 1995)	
)	
Title: HYBRIDIZATION ASSAY USING)	
SELF-QUENCHING)	
FLUORESCENCE PROBE)	

POWER OF ATTORNEY BY ASSIGNEE
TO EXCLUSION OF INVENTOR UNDER 37 C.F.R. § 3.71
WITH REVOCATION OF PRIOR POWERS

Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

The undersigned ASSIGNEE of the entire interest in the above-identified application for letters patent hereby appoints Paul Davis, Reg. No. 29,294, Mark A. Haynes, Reg. No. 30,846, David J. Weitz, Reg. No. 38,362, Kent R. Richardson, Reg. No. 39,443, and Paula N. Chavez, Reg. No. 34,798 to prosecute this application and transact all business in the United States Patent and Trademark Office in connection therewith and hereby revokes all prior powers of attorney; said appointment to be to the exclusion of the inventors and the inventors' attorneys in accordance with the provisions of 37 C.F.R. § 3.71.

The following evidentiary documents establish a chain of title from the original owner to the Assignee:

X a copy of an Assignment attached hereto, which Assignment has been (or is herewith) forwarded to the Patent and Trademark Office for recording; or

___ the Assignment recorded on _____ at reel ___, frames ___ - ___.

Pursuant to 37 C.F.R. § 3.73(b) the undersigned Assignee hereby states that evidentiary documents have been reviewed and hereby certifies that, to the best of ASSIGNEE's knowledge and belief, title is in the identified ASSIGNEE.

Direct all telephone calls to **David J. Weitz**, (415) 233-0188.

Address all correspondence to:

Paul Davis
HAYNES & DAVIS
2180 Sand Hill Road, Suite 310
Menlo Park, California 94025-6935

ASSIGNEE: Perkin-Elmer Corporation

Name: Michael Hunkapiller
(Signature)

Name: Michael Hunkapiller
(Print or Type)

Title: Vice President

Date: 3/6/1996

JOINT TO CORPORATE ASSIGNMENT

WHEREAS, the undersigned,

(1) Kenneth J. Livak

(3) Jeffrey Marmaro

(hereinafter termed "Inventors"), residents of

(1) United States of America

(3) United States of America

respectively, Cities of

(1) San Jose

(3) Aurora

respectively, Counties of

(1) Santa Clara

(3) Denver

respectively, States of

(1) California

(3) Colorado

(2) Susan J. A. Flood

(4) Khairuzzaman Basnar Mullah

(2) United States of America

(4) Bangladesh

(2) Fremont

(4) Union City

(2) Contra Costa

(4) Contra Costa

(2) California

(4) California

respectively, have invented certain new and useful improvements in:

HYBRIDIZATION ASSAY USING SELF-QUENCHING FLUORESCENCE PROBE

and have executed a declaration or oath for an application for a United States patent disclosing and identifying the invention:

X On the

(1) 11th day of March, 1996;

(2) 14th day of March, 1996;

(3) 8th day of March, 1996;

(4) 7th day of March, 1996.

respectively;

Or

Said application having Application Number / and filed on the day of , 19

WHEREAS Perkin-Elmer Corporation (hereinafter termed "Assignee"), a corporation of California, having a place of business at 850 Lincoln Centre Drive, Foster City, CA 94404, wishes to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered jointly or severally by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, certificates of invention and other forms of protection thereon (hereinafter termed "patents" applied for or granted in the United States and/or other countries.

NOW THEREFORE, for good and valuable consideration acknowledged by each of said Inventors to have been received in full from said Assignee:

1. Said Inventors do hereby sell, assign, transfer and convey to said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply in any or all countries of the world for patents, certificates of inventions or other governmental grants on said invention, including the right to apply for patents pursuant to the International Convention for the Protection of Industrial Property or pursuant to any other convention, treaty, agreement or understanding; (c) in and to any and all applications filed and any and all patents, certificates of inventions or other governmental grants granted on said invention in the United States or any other country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; (d) in and to each and every reissue or extension of any of said patents; and (e) in and to each and every patent claim resulting from a reexamination certificate for any and all of said patents.

2. Said Inventors hereby jointly and severally covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and other countries. Such cooperation by said Inventors shall include prompt production of pertinent facts and documents, giving of testimony, executing of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for complying with any duty of disclosure; (c) for prosecuting any of said applications; (d) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (e) for filing and prosecuting applications for reissue of any of said patents; (f) for interference or other priority proceedings involving said invention; and (g) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, reexamination proceedings, compulsory licensing proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventors in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this Assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventors, their respective heirs, legal representatives and assigns.

4. Said Inventors hereby jointly and severally warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, the said Inventors have executed and delivered this instrument to said Assignee on the date of acknowledgment before the Notary Public as given below.


(1) Kenneth J. Livak
Kenneth J. Livak

(1) State of California
County of San Mateo

On 11 March 1996 before me, Meredith McIntosh notary public personally appeared Kenneth Livak personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Meredith McIntosh
Signature



(2) Susan J. Flood
Susan J.A. Flood



(2) State of California

County of San Mateo

On 14 March 1996 before me, Meredith McIntosh, notary public personally appeared Susan Flood personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Meredith McIntosh
Signature



(3) _____
Jeffrey Mamaro

(3) State of _____

County of _____

On _____ before me, _____ personally appeared _____ personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Signature

(4) Khairuzzaman Bashar Mullah
Khairuzzaman Bashar Mullah


(4) State of California

County of San Mateo

On 7 March 1996 before me, Meredith McIntosh, notary public personally appeared K.B. Mullah personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Meredith McIntosh
Signature



(2) _____
Susan J.A. Flood

(2) State of _____
County of _____

On _____ before me, _____ personally appeared _____ personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Signature

(3) Jeffrey Marmaro
Jeffrey Marmaro
Marmaro

(3) State of Colorado
County of Denver

On 3/8/96 before me, Jeff M Marmaro, personally appeared Jeff M Marmaro (personally known to me) (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Beth A Rodasta
Signature
My Commission Expires 12/14/99

BETH A. RODASTA
NOTARY PUBLIC
STATE OF COLORADO

(4) _____
Khairuzzaman Bashar Mullah

(4) State of _____
County of _____

On _____ before me, _____ personally appeared _____ personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Signature